- Trial Phase
- Phase 3
- Time to Market
- If pivotal Phase 3 succeeds, an NDA submission would likely follow in 2027–2028, putting potential launch at earliest 2028–2029.
- Why 7/10
- The lead asset's pivotal Phase 3 interim analysis is the next hard catalyst, triggered today (July 6, 2026) by enrollment completion of 247 patients. Results expected Q4 2026–Q1 2027. This is a dated binary ~3–9 months out on the company's major value driver, though Can-Fite also has a separate Namodenoson pipeline.
The interim analysis (results Q4 2026–Q1 2027) is the key binary. Positive data showing superiority vs placebo and non-inferiority vs Otezla would be a major derisking event for a stock near 52-week lows. However, severe cash-burn (only ~$6.5M as of mid-2025, frequent dilutive offerings) means investors face significant dilution risk before any potential commercialization. Watch for the interim data readout and any partnering/licensing deals that improve the cash runway.
Price Chart
Executive Summary
Piclidenoson is Can-Fite BioPharma's lead anti-inflammatory drug candidate, a first-in-class oral A3 adenosine receptor agonist in pivotal Phase 3 testing for moderate-to-severe plaque psoriasis. It has demonstrated a compelling safety profile (comparable to placebo, superior to leading oral drug Otezla) across 2,000+ patients, though prior data showed modestly lower efficacy than Otezla on standard skin-clearance measures. The current pivotal Phase 3 trial just hit its enrollment milestone on July 6, 2026, triggering an interim analysis whose results (expected Q4 2026–Q1 2027) represent the stock's next major binary catalyst. The oral psoriasis market is growing crowded (Otezla, Sotyktu, newly-approved Icotyde from J&J), raising commercial risk. Can-Fite is pre-revenue with severe cash constraints ($6.45M as of mid-2025) and frequent dilutive fundraising, though it has out-licensing partners in Canada, Europe, and veterinary applications that provide non-dilutive upside.
How It Works
Piclidenoson is a small-molecule pill taken twice daily. It works by activating the A3 adenosine receptor (A3AR), a protein on cell surfaces involved in regulating inflammation. By turning on this receptor, the drug reduces inflammatory signals (interleukin-17 and interleukin-23) and helps calm the overactive immune response that causes psoriasis flare-ups. Its key advantage is that it's an oral drug (not an injection) and has shown a safety profile nearly identical to placebo in trials — unlike many existing psoriasis treatments that carry significant side effects.
Trial Status
On July 6, 2026, Can-Fite announced completion of enrollment of the first 247 patients in its pivotal Phase 3 trial for moderate-to-severe plaque psoriasis, triggering a pre-specified interim analysis under an FDA- and EMA-agreed protocol. Interim results are expected in Q4 2026 or Q1 2027. The prior COMFORT-1 Phase 3 trial (529 patients) was published Jan 2024 in JEADV and met its primary endpoint at the 3mg BID dose, though showed lower efficacy vs Otezla on PASI-75.
The Two-Sided Case
Upcoming Catalysts
- Piclidenoson Phase 3 psoriasis interim analysis results — expected Q4 2026 or Q1 2027 (just triggered by 247-patient enrollment completion on July 6, 2026)
- Vetbiolix Phase 2 canine osteoarthritis data for Piclidenoson — expected Q3 2026 (veterinary licensing deal worth up to $325M in milestones)
- Potential FDA/EMA registration submissions — if interim is positive, company may accelerate NDA/MAA planning
- Namodenoson Phase 3 HCC and Phase 2b MASH readouts — also in 2026, could provide portfolio diversification
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Can-Fite BioPharma Ltd. 6-K CANF ·Originating report